Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease [5]

Rheumatology

Volumn 45, Issue 4, 2006, Pages 490-491

  Rech, Juergen ^a   Kallert, S ^a   Hueber, A J ^a   Requadt, C ^a   Kalden, J R ^a   Schulze Koops, H ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID;

ADULT; ANAMNESIS; ANEMIA; ANTIBODY DETECTION; CASE REPORT; CATARACT EXTRACTION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CLINICAL PROTOCOL; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; IMMUNOADSORPTION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; LIVER DYSFUNCTION; MIXED CONNECTIVE TISSUE DISEASE; NECROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; TREATMENT OUTCOME;

EID: 33645327160     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei271     Document Type: Letter

References (10)

1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972;52:148-59.
2. Bennett RM, O'Connell DJ. The arthritis of mixed connective tissue disease. Ann Rheum Dis 1978;37:397-403.
3. Maddison PJ. Mixed connective tissue disease: Overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 2000;14:111-24.
4. Bennett RM. Mixed connective tissue disease and over overlap syndromes. In: Kelley W, Harris EDJ, Ruddy SH, Sledge G, eds. Textbook of rheumatology. Philadelphia: W.B. Saunders, 2000:1240.
5. Sharp GC. Therapy and prognosis of MCTD. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Excerpta Medica, 1987:315.
6. Ulmer A, Kotter I, Pfaff A, Fierlbeck G. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J Am Acad Dermatol 2002;46:123-7.
7. Morton SJ, Powell RJ. An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: Limitations of its use. Ann Rheum Dis 2000;59:487-9.
8. Dequecker J, Geusens P, Wielands L. Short and longterm experience with plasmapheresis in connective tissue diseases. Biomedicine 1980;32:189-4.
9. Arzoo K, Sadeghi S, Liebmann HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-4.
10. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004;4:398-402.